Future Fund LLC Increases Stock Holdings in Globus Medical, Inc. $GMED

Future Fund LLC increased its position in shares of Globus Medical, Inc. (NYSE:GMED) by 27.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,158 shares of the medical device company’s stock after purchasing an additional 11,147 shares during the period. Globus Medical makes up about 1.6% of Future Fund LLC’s portfolio, making the stock its 6th biggest holding. Future Fund LLC’s holdings in Globus Medical were worth $4,494,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in GMED. Invesco Ltd. grew its holdings in Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after buying an additional 3,595,339 shares in the last quarter. Bank of Montreal Can lifted its holdings in shares of Globus Medical by 15,317.1% during the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after buying an additional 3,351,380 shares in the last quarter. Sculptor Capital LP boosted its position in shares of Globus Medical by 31.9% in the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after acquiring an additional 667,850 shares during the period. Madison Avenue Partners LP boosted its position in shares of Globus Medical by 3.0% in the fourth quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company’s stock valued at $229,167,000 after acquiring an additional 76,588 shares during the period. Finally, Alliancebernstein L.P. boosted its position in shares of Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after acquiring an additional 1,908,795 shares during the period. 95.16% of the stock is currently owned by institutional investors.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: GMED’s one-year rally has been attributed to strong growth in both business segments, rising technology adoption, and a debt-free balance sheet, reinforcing confidence in the company’s operating momentum. GMED Stock Surges 43.6% in a Year: What’s Driving the Rally?
• Positive Sentiment: Wall Street still appears constructive on Globus Medical, with Truist reiterating a buy rating even after lowering its price target to $100, which still implies meaningful upside from recent levels. Globus Medical (NYSE:GMED) Price Target Lowered to $100.00 at Truist Financial
• Positive Sentiment: Recent commentary also says GMED still looks undervalued after its recent gains, which may be attracting value-oriented investors. Globus Medical (GMED) Stock Still Looks Undervalued Despite A 39% Return
• Positive Sentiment: Zacks highlighted GMED as a strong value stock, supporting the view that the shares may still have room to run if fundamentals remain solid. Here’s Why Globus Medical (GMED) is a Strong Value Stock
• Neutral Sentiment: The company scheduled its second-quarter 2026 earnings release for August 6, which keeps investors focused on upcoming results and guidance, but does not by itself change the investment thesis. Globus Medical Schedules Second Quarter Earnings Release and Conference Call
• Neutral Sentiment: Globus Medical also announced it will host a conference call to discuss second-quarter results, increasing visibility into the business ahead of earnings. Globus Medical to Announce Second Quarter 2026 Financial Results on August 6
• Negative Sentiment: A shareholder litigation firm said it is investigating possible fiduciary-duty breaches by certain officers and directors, which could create overhang and governance concerns for GMED. Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on GMED shares. Stifel Nicolaus lowered their price target on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research report on Wednesday, July 8th. Truist Financial cut their price objective on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday. Zacks Research lowered shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Wells Fargo & Company decreased their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $103.75.

Globus Medical Stock Performance

GMED opened at $77.01 on Friday. The firm has a market cap of $10.45 billion, a P/E ratio of 17.91, a price-to-earnings-growth ratio of 1.67 and a beta of 0.95. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The business’s fifty day moving average is $79.84 and its 200-day moving average is $86.47.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the previous year, the firm earned $0.68 earnings per share. Globus Medical’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company’s stock, valued at $41,201,733. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 18.38% of the stock is currently owned by corporate insiders.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.